Prevalence and Pattern of GATA3 Immunohistochemical Expression in Female Genital Tract Adenocarcinomas.

Q3 Medicine

Iranian Journal of Pathology Pub Date : 2024-01-01 Epub Date: 2024-01-29 DOI:10.30699/IJP.2024.2016228.3217

Elham Mirzaian, Tahereh Doustmohammadi, Mahshid Panahi, Soheila Sarmadi, Fereshteh Ameli, Fatemeh Nili

{"title":"Prevalence and Pattern of GATA3 Immunohistochemical Expression in Female Genital Tract Adenocarcinomas.","authors":"Elham Mirzaian, Tahereh Doustmohammadi, Mahshid Panahi, Soheila Sarmadi, Fereshteh Ameli, Fatemeh Nili","doi":"10.30699/IJP.2024.2016228.3217","DOIUrl":null,"url":null,"abstract":"Background & objective: GATA3 immunohistochemistry has been described as a highly sensitive marker in determining carcinomas of breast and urothelial origin. In the gynecologic system, it can be used as a marker to diagnose mesonephric or mesonephric-like carcinomas and trophoblastic tumors. The present study was performed to determine the diagnostic value of GATA3 in gynecological adenocarcinomas.Methods: A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.Results: A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.Conclusion: GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.","PeriodicalId":38900,"journal":{"name":"Iranian Journal of Pathology","volume":"19 2","pages":"218-224"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11304466/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30699/IJP.2024.2016228.3217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background & objective: GATA3 immunohistochemistry has been described as a highly sensitive marker in determining carcinomas of breast and urothelial origin. In the gynecologic system, it can be used as a marker to diagnose mesonephric or mesonephric-like carcinomas and trophoblastic tumors. The present study was performed to determine the diagnostic value of GATA3 in gynecological adenocarcinomas.

Methods: A total of 187 samples from different types of endometrial, endocervical, and ovarian carcinomas were analyzed for intensity and percentage of GATA3 expression in tumor cells. The relationship between GATA3 expression and clinicopathological parameters was investigated.

Results: A total of 187 patients including 101 ovarian, 77 endometrial, and 9 endocervical adenocarcinomas were investigated. Weak and focal expression of this marker was observed in 5. 1% (4/77) endometrial, 12.9% (13/101) ovarian, and 11.1% (1/9) endocervical adenocarcinomas. The mean H score in all subtypes was less than 10.6 (2-35). There was no statistically significant correlation between GATA3 expression in tumor cells with clinical stage, and tumor recurrence or metastasis.

Conclusion: GATA3 is infrequently, weak, or focally expressed in most of the common gynecological adenocarcinomas.

查看原文本刊更多论文

女性生殖道腺癌中 GATA3 免疫组化表达的发生率和模式

背景与目的：GATA3 免疫组织化学已被描述为确定乳腺癌和尿道癌的高度敏感标记物。在妇科系统中，它可作为诊断肾间质或肾间质样癌和滋养细胞肿瘤的标志物。本研究旨在确定 GATA3 在妇科腺癌中的诊断价值：方法：共分析了 187 份不同类型的子宫内膜癌、宫颈内膜癌和卵巢癌样本，检测肿瘤细胞中 GATA3 的表达强度和百分比。研究了 GATA3 表达与临床病理参数之间的关系：共调查了 187 例患者，包括 101 例卵巢癌、77 例子宫内膜癌和 9 例宫颈内膜腺癌。在 5.1%（4/77）子宫内膜腺癌、12.9%（13/101）卵巢腺癌和 11.1%（1/9）宫颈内膜腺癌中观察到该标记物的弱和局灶性表达。所有亚型的平均 H 评分均低于 10.6（2-35）。GATA3在肿瘤细胞中的表达与临床分期、肿瘤复发或转移之间没有统计学意义上的相关性：结论：GATA3在大多数常见妇科腺癌中很少表达、表达较弱或局部表达。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊